This is a prospective, non-blinded, multi-arm study. Patients at 18 - 70 years old with liver cancer will be enrolled.~The approach is to identify novel proteomic biomarkers for HCC patients treated with Lipiodol TACE using beads-based X-aptamer library, then validate and create a biomarker panel that can be used to predict the outcome of HCC post-Lipiodol TACE treatment.~Lipiodol TACE will be done as standard of care and the only thing done as research will be blood draws pre and post-TACE.
This study will enroll patients being planned for TACE, obtain blood samples pre and post TACE for biomarker identification using bead based X-aptamer library. No intervention is planned.